SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1/A
Document Type: S-1/A
Date Filed: 2026-05-15
Accession Number: 0001493152-26-023752
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226023752/forms-1a.htm

Chunk 73 of 94
Word Count: 1440
Character Count: 9212

Document Content:

or cause to be filed any registration statement with the SEC relating to this offering of any shares of our capital stock or any securities convertible into or exercisable or exchangeable for shares of our capital stock. Tail Financing The Representative will also be entitled to an aggregate additional fee of seven percent (7%) of the gross proceeds of future financings and warrants to purchase up to five percent (5%) of the number of securities sold in future financings consummated solely with investors with whom we have had a conference call or a meeting arranged by the Representative prior to the expiration or termination of the Engagement Letter; provided that the future financing is consummated at any time within the twelve (12) month period following the earlier to occur of (i) the expiration or termination of the Engagement Letter or (ii) the closing of this offering. Right of First Refusal

have granted the Representative the right to act as lead or joint-lead investment banker, lead or joint book-runner, lead or joint placement
agent and/or investment banker/advisor, for any of our future public and private equity and debt offerings, including all equity linked
financings, during the twelve (12) month period following the completion of this offering in compliance with FINRA Rule 5110(g)(6).

Determination
of Offering Price

Prior
to this offering, there has been no public market for our common stock. The public offering price was negotiated between the Representative
and us. In determining the public offering price of our common stock, the Representative considered:

●	the
history and prospects for the industry in which we compete;

●	our
financial information;

●	the
ability of our management and our business potential and earning prospects;

●	the
prevailing securities markets at the time of this offering; and

●	the
recent market prices of, and the demand for, publicly traded shares of generally comparable
companies, as well as the recent market price of our common stock.

Listing

have applied to have our common stock listed on Nasdaq under the symbol “BVXX”. In order to meet one of the requirements
for listing our common stock on Nasdaq, the underwriters have undertaken to sell lots of 100 or more shares to a minimum of 300 beneficial
holders.

Stabilization

connection with this offering, the underwriters may engage in stabilizing transactions, over-allotment transactions, syndicate-covering
transactions, penalty bids, and purchases to cover positions created by short sales.

●	Stabilizing
transactions permit bids to purchase securities so long as the stabilizing bids do not exceed
a specified maximum and are engaged in for the purpose of preventing or retarding a decline
in the market price of the securities while this offering is in progress.

●	Over-allotment
transactions involve sales by the underwriters of securities in excess of the number of securities
the underwriters are obligated to purchase. This creates a syndicate short position which
may be either a covered short position or a naked short position. In a covered short position,
the number of securities over-allotted by the underwriters is not greater than the number
of securities that they may purchase in the over-allotment option. In a naked short position,
the number of securities involved is greater than the number of securities in the over-allotment
option. The underwriters may close out any short position by exercising their over-allotment
option and/or purchasing securities in the open market.

●	Syndicate
covering transactions involves purchases of securities in the open market after the distribution
has been completed in order to cover syndicate short positions. In determining the source
of securities to close out the short position, the underwriters will consider, among other
things, the price of securities available for purchase in the open market as compared with
the price at which they may purchase securities through exercise of the over-allotment option.
If the underwriters sell more securities than could be covered by exercise of the over-allotment
option and, therefore, have a naked short position, the position can be closed out only by
buying securities in the open market. A naked short position is more likely to be created
if the underwriters are concerned that after pricing there could be downward pressure on
the price of the securities in the open market that could adversely affect investors who
purchase in this offering.

●	Penalty
bids permit the underwriters to reclaim a selling concession from a syndicate member when
the securities originally sold by that syndicate member are purchased in stabilizing or syndicate
covering transactions to cover syndicate short positions.

These
stabilizing transactions, over-allotment transactions, syndicate covering transactions, and penalty bids may have the effect of raising
or maintaining the market price of our securities or preventing or retarding a decline in the market price of our securities. As a result,
the price of our securities in the open market may be higher than it would otherwise be in the absence of these transactions. Neither
we nor the underwriters make any representation or prediction as to the effect that the transactions described above may have on the
price of our securities. These transactions may be affected on the Nasdaq Stock Market, in the over-the-counter market or otherwise and,
if commenced, may be discontinued at any time.

Passive
Market Making

connection with this offering, underwriters, and selling group members may engage in passive market making transactions in our securities
on the Nasdaq Stock Market in accordance with Rule 103 of Regulation M under the Exchange Act, during a period before the commencement
of offers or sales of the shares and extending through the completion of the distribution. A passive market maker must display its bid
at a price not in excess of the highest independent bid of that security. However, if all independent bids are lowered below the passive
market maker’s bid, then that bid must then be lowered when specified purchase limits are exceeded.

Other
Relationships

The
underwriters and their respective affiliates are full service financial institutions engaged in various activities, which may include
sales and trading, commercial and investment banking, advisory, investment management, investment research, principal investment, hedging,
market making, brokerage and other financial and non-financial activities and services. Certain of the underwriters and their respective
affiliates have provided, and may in the future provide, a variety of these services to us and to persons and entities with relationships
with us, for which they received or will receive customary fees and expenses.

Offer
Restrictions Outside the United States

Other
than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities offered
by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be
offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with
the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result
in compliance with the applicable rules and regulations of that jurisdiction. Persons who come into possession of this prospectus are
advised to inform themselves about and to observe any restrictions relating to this offering and the distribution of this prospectus.
This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in
any jurisdiction in which such an offer or a solicitation is unlawful.

Selling
Restrictions

Australia

This
prospectus:

●	does
not constitute a disclosure document or a prospectus under Chapter 6D.2 of the Corporations
Act 2001 (Cth), or the Corporations Act;

●	has
not been, and will not be, lodged with the Australian Securities and Investments Commission,
or ASIC, as a disclosure document for the purposes of the Corporations Act and does not purport
to include the information required of a disclosure document for the purposes of the Corporations
Act; and

●	may
only be provided in Australia to select investors who are able to demonstrate that they fall
within one or more of the categories of investors, available under section 708 of the Corporations
Act, or Exempt Investors.

The
securities may not be directly or indirectly offered for subscription or purchased or sold, and no invitations to subscribe for or buy
the securities may be issued, and no draft or definitive offering memorandum, advertisement or other offering material relating to any
securities may be distributed in Australia, except where disclosure to investors is not required under Chapter 6D of the Corporations
Act or is otherwise in compliance with all applicable Australian laws and regulations. By submitting an application for the securities,
you represent and warrant to us that you are an Exempt Investor.